… In addition, apolipoprotein E (APOE), the major genetic risk factor for lateonset AD, has … .,
2013b) as well as a greater proportion of men (Mormino et al., 2014a). Non-AD pathologies are …

Introduction Precision medicine methodologies and approaches have advanced our
understanding of the clinical presentation, development, progression, and management of …

Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept
that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in …

… 1E). There were also NC subjects that did not have any indication of elevated DVR values
… 1D–E) were removed from each regression model. In this subset analysis (n = 18), the PIB …

Background: The PET tracer 11 C-labeled Pittsburgh Compound-B ( 11 C-PIB) specifically
binds fibrillar amyloid-beta (Aβ) plaques and can be detected in Alzheimer disease (AD). We …

Objective Detection of focal brain tau deposition during life could greatly facilitate accurate
diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and …

… Receiver operator characteristic (ROC) analyses were performed to compare the
discriminatory power of PiB index and FDG Z difference in our dataset (figure e-3). The ROC-derived …

Importance Positron emission tomography (PET) imaging now allows in vivo visualization of
both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau …

Objective Alzheimer's disease (AD) is found at autopsy in up to one third of patients with
primary progressive aphasia (PPA), but clinical features that predict AD pathology in PPA are …

Objective To assess the association between lifestyle practices (cognitive and physical activity)
and β-amyloid deposition, measured with positron emission tomography using carbon 11…